Purple Biotech (PPBT) to Release Quarterly Earnings on Saturday

Purple Biotech (NASDAQ:PPBT) is expected to issue its Q1 2026 results before the market opens on Saturday, May 16th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter.

Purple Biotech (NASDAQ:PPBT) last announced its earnings results on Friday, March 13th. The company reported ($19.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.40) by ($16.45). On average, analysts expect Purple Biotech to post $-17 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Purple Biotech Stock Up 7.5%

Shares of NASDAQ PPBT traded up $0.28 during trading on Friday, hitting $3.97. The company had a trading volume of 11,891 shares, compared to its average volume of 12,307. The stock has a fifty day simple moving average of $4.21 and a two-hundred day simple moving average of $5.96. Purple Biotech has a fifty-two week low of $3.49 and a fifty-two week high of $29.00. The firm has a market capitalization of $5.10 million, a price-to-earnings ratio of -0.19 and a beta of 0.68.

Analyst Upgrades and Downgrades

PPBT has been the topic of several research analyst reports. Zacks Research upgraded shares of Purple Biotech from a “strong sell” rating to a “hold” rating in a research report on Monday, April 13th. Weiss Ratings lowered shares of Purple Biotech from a “sell (e+)” rating to a “sell (e)” rating in a research report on Monday, May 4th. Finally, HC Wainwright lowered their price target on shares of Purple Biotech from $34.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, March 13th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $30.00.

Hedge Funds Weigh In On Purple Biotech

An institutional investor recently bought a new position in Purple Biotech stock. SmartHarvest Portfolios LLC purchased a new position in shares of Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 47,454 shares of the company’s stock, valued at approximately $31,000. SmartHarvest Portfolios LLC owned about 0.37% of Purple Biotech at the end of the most recent quarter. 9.64% of the stock is owned by hedge funds and other institutional investors.

About Purple Biotech

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage.